Organization (Academic)
Shanxi Medical University
ClinicalTrials.gov lists Shanxi Medical University as lead sponsor of 14 trials, counting the companies grouped under it. Shanxi Medical University itself has 12 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Shanxi Medical University and 1 company grouped under it: 14 lead-sponsored trials (10 its own, 4 in the grouped companies) and 2 legal-entity registrations (1 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Shanxi Provincial People’s Hospital | 4 | 1 |
Disease areas (59)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Hepatitis B | 6 |
| Fibrosis | 4 |
| Intracranial Aneurysm | 3 |
| Liver Cirrhosis | 3 |
| Renal Insufficiency, Chronic | 3 |
Showing 5 of 59 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 1 |
| 2019 | 3 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2014 | 2 |
| 2013 | 1 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (12)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| 20 µg recombinant hepatitis B vaccine at months 0, 1, and 6 | 3 |
| 20 µg dose hepatitis B vaccine | 3 |
| 60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6 | 3 |
| 20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6 | 3 |
| 60 µg dose hepatitis B vaccine | 2 |
Showing 5 of 12 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| not enough data | 2 of 2 on time (n=2) |
Journals published in (99)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of hepatology | 5 |
| Anesthesiology | 4 |
| British journal of anaesthesia | 4 |
| Expert review of vaccines | 4 |
| BMJ open | 3 |
Showing 5 of 99 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 1 | 2023-04-04 |
Organization relationships (46)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| First Affiliated Hospital of Harbin Medical University | Co sponsors trial with | 3 |
| The First Hospital of Jilin University | Co sponsors trial with | 2 |
| The First Affiliated Hospital of Shanxi Medical University | Co sponsors trial with | 2 |
| Qilu Hospital of Shandong University | Co sponsors trial with | 1 |
| First Affiliated Hospital of Jinan University | Co sponsors trial with | 1 |
Showing 5 of 46 relationships.
Latest dated events (64)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 64 events.
Biomarker capability evidence (3)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ARMC5 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| CD4 | Trial sponsor | Named in trial exclusion criteria |
| CD4 | Trial sponsor | Mentioned in trial text |
Biomarkers this organization publishes on (163)
Shown in this order: most publications first.
Showing 5 of 163 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.